Profile data is unavailable for this security.
About the company
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-47.99m
- Incorporated1998
- Employees40.00
- LocationViracta Therapeutics Inc2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA 92007United StatesUSA
- Phone+1 (858) 400-8470
- Fax+1 (650) 266-3501
- Websitehttps://www.viracta.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aptorum Group Ltd | 431.38k | -2.82m | 24.73m | 3.00 | -- | 0.9427 | -- | 57.33 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
Equillium Inc | 37.89m | -12.13m | 25.14m | 44.00 | -- | 1.19 | -- | 0.6633 | -0.3476 | -0.3476 | 1.08 | 0.5983 | 0.6568 | -- | 8.95 | 861,227.30 | -21.02 | -46.81 | -39.66 | -57.36 | -- | -- | -32.01 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
Aspira Women's Health Inc | 8.99m | -14.74m | 25.40m | 64.00 | -- | -- | -- | 2.82 | -1.33 | -1.33 | 0.8698 | -0.1104 | 0.9637 | 13.76 | 5.83 | 140,484.40 | -158.00 | -110.58 | -395.41 | -151.88 | 58.84 | 45.23 | -163.95 | -334.08 | 1.11 | -- | 3.10 | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
AIM ImmunoTech Inc | 193.00k | -31.12m | 25.65m | 26.00 | -- | 5.45 | -- | 132.92 | -0.637 | -0.637 | 0.004 | 0.096 | 0.0072 | -- | 0.2189 | 7,423.08 | -116.00 | -45.64 | -148.40 | -48.35 | 74.09 | -231.75 | -16,123.32 | -11,695.01 | -- | -- | 0.3478 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
Oncternal Therapeutics Inc | 1.15m | -36.38m | 26.00m | 27.00 | -- | 1.13 | -- | 22.59 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
Correlate Energy Corp | 7.95m | -13.85m | 26.08m | 19.00 | -- | -- | -- | 3.28 | -0.3747 | -0.3747 | 0.2157 | -0.145 | 2.76 | -- | 26.10 | 418,160.50 | -481.76 | -315.47 | -- | -- | 17.98 | 15.42 | -174.38 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
Trinity Biotech plc (ADR) | 56.71m | -33.88m | 26.31m | 380.00 | -- | -- | -- | 0.464 | -4.42 | -2.81 | 7.41 | -14.96 | 0.625 | 1.69 | 3.67 | 149,229.00 | -37.34 | -20.30 | -47.55 | -29.54 | 34.21 | 39.92 | -59.75 | -29.86 | 1.03 | -1.96 | 1.36 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
Shineco Inc | 5.62m | -14.34m | 26.36m | 87.00 | -- | 0.7325 | -- | 4.69 | -3.98 | -2.32 | 1.36 | 5.58 | 0.0664 | 0.48 | 1.45 | 64,633.68 | -19.79 | -12.77 | -38.28 | -16.84 | 12.77 | 25.88 | -298.09 | -102.06 | 0.4842 | -8.14 | 0.3908 | -- | -- | -58.35 | -33.86 | -- | -- | -- |
Qilian International Holding Group Ltd | 46.47m | -7.78m | 26.44m | 298.00 | -- | 0.618 | -- | 0.569 | -0.2176 | -0.2176 | 1.30 | 1.20 | 0.8027 | 6.45 | 33.30 | 155,944.60 | -14.03 | 2.71 | -16.84 | 3.86 | 3.77 | 11.66 | -17.48 | 2.72 | 4.43 | -0.4812 | 0.0107 | 26.11 | -28.35 | -1.60 | -822.64 | -- | 12.86 | -- |
Viracta Therapeutics Inc | 0.00 | -47.99m | 26.46m | 40.00 | -- | 4.70 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
Spruce Biosciences Inc | 10.13m | -46.75m | 26.74m | 22.00 | -- | 0.4013 | -- | 2.64 | -1.15 | -1.15 | 0.2483 | 1.62 | 0.0894 | -- | -- | 349,206.90 | -41.26 | -41.24 | -50.47 | -46.49 | -- | -- | -461.67 | -1,774.39 | -- | -114.54 | 0.0423 | -- | -- | -- | -3.77 | -- | -- | -- |
Biora Therapeutics Inc | 544.00k | -111.08m | 26.82m | 58.00 | -- | -- | -- | 49.30 | -7.13 | -7.12 | 0.0267 | -3.29 | 0.0143 | -- | 0.6594 | 9,379.31 | -291.43 | -122.84 | -482,965.20 | -369.01 | -- | -- | -20,419.48 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
Alterola Biotech Inc | 0.00 | -2.88m | 27.31m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
Janone Inc | 0.00 | -18.58m | 27.54m | 5.00 | -- | -- | -- | -- | -3.66 | -3.95 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -69.38 | -23.12 | -88.46 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.1264 | -- | -- | -- | -313.15 | -- | -- | -- |
IGC Pharma Inc | 1.22m | -14.15m | 27.77m | 61.00 | -- | 2.94 | -- | 22.84 | -0.2479 | -0.2479 | 0.0217 | 0.142 | 0.0776 | 0.2084 | 7.09 | 19,934.43 | -90.30 | -33.35 | -100.90 | -35.84 | 51.40 | 8.74 | -1,163.24 | -410.26 | 0.8564 | -- | 0.0153 | -- | 129.47 | -16.11 | 23.38 | -- | 25.28 | -- |
BioVie Inc | 0.00 | -37.18m | 28.07m | 18.00 | -- | 1.48 | -- | -- | -0.9626 | -0.9626 | 0.00 | 0.3104 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
BVF Partners LPas of 31 Mar 2024 | 3.61m | 9.20% |
Citadel Advisors LLCas of 31 Mar 2024 | 1.52m | 3.87% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.15m | 2.94% |
Laurion Capital Management LPas of 31 Mar 2024 | 420.43k | 1.07% |
MAI Capital Management LLCas of 31 Mar 2024 | 364.10k | 0.93% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 298.44k | 0.76% |
Aisling Capital Management LPas of 31 Mar 2024 | 288.57k | 0.74% |
Medical Strategy GmbHas of 30 Nov 2023 | 278.12k | 0.71% |
Geode Capital Management LLCas of 31 Mar 2024 | 252.70k | 0.64% |
Apo Asset Management GmbHas of 30 Sep 2023 | 252.15k | 0.64% |